Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
INDIANAPOLIS, March 05, 2018 -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced that Derek Small, Assembly’s president and chief executive officer, will present at the Cowen Annual Healthcare Conference in Boston on Wednesday, March 14, 2018 at 10:00 a.m ET.
A live audio webcast of the presentation will be available at investor.assemblybio.com, and a replay will be available for approximately 30 days.
About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. Assembly’s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Assembly is developing a robust pipeline of product candidates in multiple disease indications. For more information, visit assemblybio.com.
Contacts
Assembly Biosciences, Inc.
Investors:
Lauren Glaser
(415) 521-3828
[email protected]
Media:
Barbara Lindheim
(212) 584-2276
[email protected]
